Starling Oncology Warrant
STLNW
12 hedge funds and large institutions have $11.2M invested in Starling Oncology Warrant in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 8 closing their positions.
168% more capital invested
Capital invested by funds: $4.18M → $11.2M (+$7.02M)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
5.02% less ownership
Funds ownership: 9.55% → 4.53% (-5%)
40% less funds holding
Funds holding: 20 → 12 (-8)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$780K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$93 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$52K |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$43K |
| 3 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
-$32K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$19.4K |
| 5 |
JG
Jefferies Group
New York
|
-$17.8K |
STLNW Hedge Fund Activity: Q1 2022 in Review
12 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Warrant (STLNW) for Q1 2022, worth a combined $11.2M — up 168% from $4.18M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of STLNW and 0 opened new positions — a net loss of 8 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was LMR Partners, adding an estimated $780K. The largest seller was Bulldog Investors, exiting entirely with an estimated $52K sold.
- 12 institutional investors held Starling Oncology Warrant (STLNW) as of Q1 2022, down from 20 in Q4 2021.
- Funds reported $11.2M of Starling Oncology Warrant stock for Q1 2022, up 168% quarter-over-quarter.
- 0 funds opened new Starling Oncology Warrant positions in Q1 2022 and 8 closed out, a net change of -8 holders.
- The largest Starling Oncology Warrant buyer in Q1 2022 was LMR Partners, an estimated $780K added.
- The largest Starling Oncology Warrant seller in Q1 2022 was Bulldog Investors, an estimated $52K sold.
Based on aggregated 13F filings for Q1 2022.